AbbVie Launches Bold Entry into Obesity Treatment with Gubra Acquisition

In a significant move to broaden its portfolio and tap into the burgeoning obesity treatment market, pharmaceutical giant AbbVie has announced a strategic deal with Danish biotech firm Gubra, potentially worth up to $2.2 billion. This collaboration marks AbbVie's ambitious entry into a sector that has seen a surge in demand as obesity rates continue to rise globally.

Continue reading